This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WESLEY W. SPINK, M.D.; F. HUGHES CRAGO, M.D.

Arch Intern Med. 1939;64(2):228-248.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sulfanilamide (paraaminobenzenesulfonamide) is effective in the treatment of infections due to beta hemolytic streptococci. Clinical and experimental observations indicate that this chemotherapeutic agent may be of value in the treatment of infections caused by the less virulent classes of streptococci. The hemolytic streptococci designated as the alpha group include Streptococcus viridans. Bliss, Long and Feinstone¹ observed that the growth of forty-two of forty-five strains of alpha hemolytic streptococci was inhibited by a 1: 10,000 concentration of the drug.² Long and Bliss³ found that sulfanilamide exerted a definite bacteriostatic effect in urine cultures of alpha streptococci. It would be desirable to ascertain the effect of sulfanilamide on the lesions of animals infected with the less virulent groups of streptococci, but such infections are not easily produced. Muether and Kinsella⁴ stated that they established bacterial endocarditis with persistent bacteremia in dogs, using a culture of nonhemolytic streptococci. After daily oral administrations of . . . [Full Text PDF of this Article]

Author Affiliations
MINNEAPOLIS

From the Department of Medicine, University Hospitals, University of Minnesota Medical School.

Footnotes
Read in part at a meeting of the Minnesota Society of Internal Medicine, June 4, 1938.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?